---
title: "U.S. stock market update: Artelo Biosciences down 8.25%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249629307.md"
description: "Artelo Biosciences fell 8.25%; Eli Lilly rose 1.55%, with a transaction volume of USD 978 million; Johnson & Johnson rose 1.42%, with a transaction volume of USD 606 million; Pfizer rose 2.41%, with a transaction volume of USD 457 million; Novo Nordisk rose 2.51%, with a market value of USD 295.4 billion"
datetime: "2025-07-22T16:53:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249629307.md)
  - [en](https://longbridge.com/en/news/249629307.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249629307.md)
generator: "portal-rs"
---

# U.S. stock market update: Artelo Biosciences down 8.25%

**U.S. Stock Market Midday Update**

Artelo Biosciences fell 8.25%. Based on recent important news:

1.  On June 11, D. Boral Capital downgraded Artelo Biosciences from Buy to Hold, leading to a decline in market confidence and putting pressure on the stock price.

2.  On July 19, Artelo Biosciences announced an ATM issuance agreement with R.F. Lafferty, planning to sell up to $6.5 million in common stock, raising concerns about equity dilution in the market.

3.  On June 30, Artelo's ART26.12 Phase I study showed no drug-related adverse events among 49 healthy volunteers; however, the market reacted lukewarmly, failing to boost the stock price.

**Stocks with High Trading Volume in the Industry**

Eli Lilly rose 1.55%, with increased trading volume. Based on recent key news:

1.  On July 21, analysts gave Eli Lilly a "Strong Buy" rating, expecting positive results from its oral GLP-1 trials and Tirzepatide drug, driving the stock price up.

2.  On July 22, Eli Lilly announced a price reduction for its weight loss drug Zepbound, increasing market accessibility and boosting investor confidence.

3.  On July 22, market reports indicated Eli Lilly's strong performance in several key markets, further enhancing market expectations for its future growth.

Johnson & Johnson rose 1.42%, with increased trading volume. Based on recent important news:

1.  On July 22, Johnson & Johnson announced a strategic agreement with Pacira Biosciences to expand market coverage for early intervention products for osteoarthritis, pushing the stock price up 1.42%.

2.  On July 21, Johnson & Johnson sought FDA approval for its new drug Icotrokinra, successfully completing Phase III trials, boosting market confidence.

3.  On July 22, Johnson & Johnson released its financial report, showing a 5.8% increase in global sales and an 18.2% increase in net profit, driving the stock price higher.

Pfizer rose 2.41%, with increased trading volume. Based on recent key news:

1.  On July 21, Pfizer and Bristol-Myers Squibb launched new direct purchase options, enhancing market confidence in its products and driving the stock price up.

2.  On July 22, analysts maintained a Hold rating on Pfizer but noted better investment options, with a positive market reaction.

3.  On July 20, Pfizer's high dividend yield attracted more investors, pushing the stock price up.

**Stocks with High Market Capitalization in the Industry**

Novo Nordisk rose 2.51%, with increased trading volume. Based on recent important news:

1.  On July 22, Novo Nordisk announced that its drug semaglutide was approved for a new indication in China, driving the stock price up 2.51%

2.  On July 21, Novo Nordisk signed a memorandum of cooperation with Ark to establish a new health management ecosystem and enhance market confidence.

3.  On July 21, Novo Nordisk reached a new agreement with WeightWatchers to expand its weight loss drug market and improve investor expectations

### Related Stocks

- [ARTL.US](https://longbridge.com/en/quote/ARTL.US.md)

## Related News & Research

- [US inflation rises below expectations in August, gives the Fed breathing space](https://longbridge.com/en/news/300635276.md)
- [BUZZ-Street View: Argon revives Google's AI standing, but questions remain](https://longbridge.com/en/news/300699265.md)
- [Netflix CEO Says Company’s Growth Not Good Enough: ‘Working on Making that Move Faster’](https://longbridge.com/en/news/300705564.md)
- [Why Did Google Stock Gain in After-Hours Trading on Wednesday?](https://longbridge.com/en/news/300646068.md)
- [Tesla (TSLA) Pushes Ahead with Sales Recovery Amid Efforts to Win Back Investors](https://longbridge.com/en/news/300668468.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**